Dolly A. Vance
2020
In 2020, Dolly A. Vance earned a total compensation of $1.2M as Executive Vice President, Corporate Affairs, General at Rigel Pharmaceuticals, a 1% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $200,770 |
|---|---|
| Option Awards | $459,869 |
| Salary | $524,890 |
| Other | $9,054 |
| Total | $1,194,583 |
Vance received $524.9K in salary, accounting for 44% of the total pay in 2020.
Vance also received $200.8K in non-equity incentive plan, $459.9K in option awards and $9.1K in other compensation.
Rankings
In 2020, Dolly A. Vance's compensation ranked 7,856th out of 13,090 executives tracked by ExecPay. In other words, Vance earned more than 40.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,856 out of 13,090 | 40th |
Division Manufacturing | 3,323 out of 5,624 | 41st |
Major group Chemicals And Allied Products | 1,347 out of 2,257 | 40th |
Industry group Drugs | 1,169 out of 1,957 | 40th |
Industry Pharmaceutical Preparations | 871 out of 1,462 | 40th |
Source: SEC filing on April 6, 2021.
Vance's colleagues
We found four more compensation records of executives who worked with Dolly A. Vance at Rigel Pharmaceuticals in 2020.